AVM Biotechnology Inc
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (NCT04366115) | AVM Biotechnology Inc | 2026-12-01 |
| The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (NCT04329728) | AVM Biotechnology Inc | 2020-11-06 |
Track AVM Biotechnology Inc automatically
Every clearance here is in the API, with alerts when new ones post.